Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation will provide up to $11 million in additional funding to 4D Molecular Therapeutics to accelerate development of 4D-710, a gene therapy for cystic fibrosis lung disease.

ReCode Therapeutics raised over $29 million in additional financing to advance its genetic medicines pipeline, including investigational therapies for cystic fibrosis.

The Cystic Fibrosis Foundation has committed up to $24 million in additional funding to Prime Medicine to advance prime editing gene therapy for cystic fibrosis patients.

Owlstone Medical has secured a $2.3 million equity investment from the Cystic Fibrosis Foundation to develop a breath test for detecting Pseudomonas aeruginosa infections in CF patients.

• AbbVie has partnered with Galapagos NV in a global alliance worth up to $406 million to discover and develop combination therapies targeting key mutations in cystic fibrosis patients. • The collaboration aims to develop oral drugs addressing F508del and G551D mutations in the CFTR protein, with plans to initiate Phase 1 clinical trials by the end of 2014. • This partnership joins other significant industry efforts to combat cystic fibrosis, including Pfizer's expanded six-year research program with the Cystic Fibrosis Foundation worth up to $58 million.

• The Cystic Fibrosis Foundation is investing $15 million in Recode Therapeutics to advance gene-editing medicines for cystic fibrosis (CF) patients without effective treatment options. • Recode Therapeutics collaborates with Intellia Therapeutics, developing a strategy to alter the genetic code, creating a healthy CFTR gene version for functional protein production. • The funding supports the development of up to three gene-correction programs, initially focusing on CF mutations not addressed by existing therapies. • Recode's RCT2100, an inhaled mRNA therapy delivering a healthy CFTR version to lung cells, is currently in Phase 1 clinical trials, expanding treatment options for all CF patients.

The RDCA-DAP has acquired new datasets from the Cystic Fibrosis Therapeutics Development Network to accelerate cystic fibrosis (CF) research and therapy development.